Mobilization and selection of peripheral blood hematopoietic progenitors in children with systemic sclerosis.

BACKGROUND AND OBJECTIVE Autologous transplant of lymphocyte-depleted peripheral blood stem cells has been proposed for treatment of patients with severe autoimmune disease. However, until now, no data are available on the safety and feasibility of both stem cell collection and selection in pediatric patients with these disorders. We report on three children affected by systemic sclerosis with lung involvement, who received chemotherapy and granulocyte colony-stimulating factor (G-CSF) to mobilize autologous peripheral blood progenitors. DESIGN AND METHODS The priming regimen consisted of cyclophosphamide (CY, 4 g/m(2)) and G-CSF (lenograstim, 10 microg/kg/day starting 2 days after cyclophosphamide administration until stem cell collection). Leukapheresis was performed when WBC and CD34+ cell count were at least 2 x 10(9)/L and 0.03 x 10(9)/L, respectively. In the first patient, positive selection of CD34+ cells was performed through the Ceprate SC stem cell concentrator (CellPro, Bothell, WA, USA). In the remaining 2 children, progenitor cells were also purged with negative selection of CD4+ and CD8+ lymphocytes performed by means of the Isolex 300i device (Baxter). RESULTS All patients tolerated the priming regimen well and did not present any sign of autoimmune disease exacerbation. Collection was successful in all children and the number of CD34+ cells before selection ranged between 10.7 x 10(6) and 17.6 x 10(6)/kg of patient body weight. The selection of haematopoietic stem cells in the 3 patients resulted in at least 2. 6-log T-cell depletion of the cell content, with a recovery of the initial value of CD34+ cells comprised between 21 and 44%. After, a preparative regimen consisting of CY (200 mg/kg over 4 days) and Campath-1 G in vivo (10 mg/day for 2 consecutive days), patients were transplanted using cryopreserved lymphocyte-depleted progenitor cells. In all cases, a prompt hematopoietic engraftment was observed. INTERPRETATION AND CONCLUSIONS Taken together these data suggest that mobilization, collection and selection of hematopoietic progenitors are safe and feasible in children with autoimmune disease.

[1]  B. Cohen,et al.  Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. , 1998, Blood.

[2]  R. Krance,et al.  BMT beats autoimmune disease , 1998, Nature Network Boston.

[3]  A. Marmont Stem cell transplantation for severe autoimmune diseases: progress and problems. , 1998, Haematologica.

[4]  L. To,et al.  The biology and clinical uses of blood stem cells. , 1997, Blood.

[5]  J. Winkler,et al.  Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation , 1997, The Lancet.

[6]  N. Schmitz,et al.  Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. , 1996, Blood.

[7]  J. Ferrara,et al.  Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. , 1995, Blood.

[8]  A. Marmont,et al.  Stem cell transplantation for severe autoimmune diseases: new proposals but still unanswered questions. , 1995, Bone marrow transplantation.

[9]  R. Laxer,et al.  Scleroderma in children. , 1995, Pediatric clinics of North America.

[10]  R. Storb,et al.  Factors that influence collection and engraftment of autologous peripheral-blood stem cells. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. T. Onundarson,et al.  Reactivation of rheumatoid arthritis and development of leukocytoclastic vasculitis in a patient receiving granulocyte colony-stimulating factor for Felty's syndrome. , 1995, The American journal of medicine.

[12]  T. Hartung,et al.  Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. , 1995, Blood.

[13]  F. Locatelli,et al.  Recombinant human G-CSF: how wide is the field of clinical applicability? , 1995, Haematologica.

[14]  T. Medsger,et al.  Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. , 1994, Arthritis and rheumatism.

[15]  A. Hirao,et al.  Effects of progenitor cell dose and preleukapheresis use of human recombinant granulocyte colony-stimulating factor on the recovery of hematopoiesis after blood stem cell autografting in children. , 1993, Experimental hematology.

[16]  A. Freemont,et al.  Sequential dermal microvascular and perivascular changes in the development of scleroderma , 1992, The Journal of pathology.

[17]  J. Yin,et al.  Resolution of immune-mediated diseases following allogeneic bone marrow transplantation for leukaemia. , 1992, Bone marrow transplantation.

[18]  D. V. van Bekkum,et al.  Remission induction of adjuvant arthritis in rats by total body irradiation and autologous bone marrow transplantation. , 1991, Bone marrow transplantation.

[19]  T. Medsger,et al.  Systemic sclerosis (scleroderma) , 1991 .

[20]  D. Eedy,et al.  Clearance of severe psoriasis after allogenic bone marrow transplantation. , 1990, BMJ.

[21]  F. Appelbaum,et al.  Regimen-related toxicity in patients undergoing bone marrow transplantation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. Jacobs,et al.  Prolonged remission of severe refractory rheumatoid arthritis following allogeneic bone marrow transplantation for drug-induced aplastic anaemia. , 1986, Bone marrow transplantation.

[23]  P H Plotz,et al.  Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. , 1986, The New England journal of medicine.

[24]  S. Ikehara,et al.  Rationale for bone marrow transplantation in the treatment of autoimmune diseases. , 1985, Proceedings of the National Academy of Sciences of the United States of America.